March 19 (Reuters) - Seelos Therapeutics said on Tuesday that its treatment for a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal of a mid-stage trial. (Reporting by Christy Santhosh; Editing by Savio D'Souza)